Rossari Biotech cash flow

Latest FY26

Cash from operations: ₹65.1cr−52.7% on FY25
Capital spending: ₹265cr+67.0% on FY25
Free cash flow: −₹200cr−₹21.1 cr in FY25
Cash from financing: ₹186cr+187.1% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	79.1	67.1	60.4	62.9
	—	27.2	17.8	19.4	22.3
	—	−1.4	−0.9	−2.2	−2.5
	—	0.0	0.0	0.1	−0.6
	—	3.3	0.1	0.7	0.9
	—	−2.3	0.3	−0.5	−0.3
	—	0.3	0.2	3.6	2.0
	—	−20.5	−1.8	−4.4	0.0
	—	−49.5	−72.8	−93.8	1.5
	—	−135	−85.4	−113	−28.0
	—	30.5	85.1	49.3	0.0
	—	0.0	0.0	0.0	−1.5
	—	1.2	2.7	0.0	0.0
Cash from operating activities
	202	201	184	177	143
	—	−66.8	12.4	−80.3	56.9
	—	134	197	97.1	200
	—	68.8	59.2	53.9	47.8
	—	65.1	137	43.3	152
Cash from investing activities
	—	265	159	131	32.9
	—	24.2	0.0	5.5	1.7
	—	0.0	17.8	9.0	0.0
	—	23.1	0.0	0.0	−13.7
	—	0.0	0.3	17.7	98.5
	—	1.2	0.0	0.1	0.2
	—	1.5	0.7	2.6	2.1
	—	−4.8	−7.8	46.6	−39.7
	—	−219	−184	−103	−181
Cash from financing activities
	—	0.8	0.0	0.0	4.2
	—	0.0	5.1	3.8	0.0
	—	240	121	43.5	65.5
	—	19.6	38.6	11.6	0.0
	—	6.6	3.0	0.8	0.0
	—	25.2	16.5	16.0	6.1
	—	2.8	2.8	2.8	2.8
	—	186	64.9	16.2	60.9
	—	31.9	18.6	−43.8	32.4
	—	−0.8	0.4	−0.3	0.0
	—	31.1	19.0	−44.0	32.4
	—	—	—	25.2	69.8
Reference items
	314	286	265	250	223
	11.8%	11.9%	12.7%	13.6%	13.5%
	−200	−200	−21.1	−88.0	120
	—	−4.8	44.6	−72.1	—
	−₹36.04	−₹36.04	−₹3.80	−₹15.89	₹21.58
	—	0.44×	1.01×	0.33×	1.42×
	—	68.8	59.2	53.9	47.8
	—	25.2	16.5	16.0	6.1

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ROSSARI₹407.60

Rossari Biotech Limited

· Chemicals

₹ CrorePeersNOCIL HSCL NAVINFLUOR DDEVPLSTIK CHEMPLASTS TATACHEM AARTIIND JGCHEMMcap ₹2,257 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	62.9	60.4	67.1	79.1	—
+ Finance Costs	22.3	19.4	17.8	27.2	—
+ Interest Income	-2.5	-2.2	-0.9	-1.4	—
+ Fair Value (Gains) / Losses	-0.6	0.1	0.0	0.0	—
+ Share-based Payments	0.9	0.7	0.1	3.3	—
+ Unrealised FX (Gain) / Loss	-0.3	-0.5	0.3	-2.3	—
+ Other Non-cash Items	2.0	3.6	0.2	0.3	—
+ Other — Cash Effects are Investing / Financing	0.0	-4.4	-1.8	-20.5	—
Changes in Working Capital
+ Inventories	1.5	-93.8	-72.8	-49.5	—
+ Trade Receivables — Current	-28.0	-112.6	-85.4	-134.9	—
+ Trade Payables — Current	0.0	49.3	85.1	30.5	—
+ Other Financial Liabilities — Current	-1.5	0.0	0.0	0.0	—
+ Provisions — Current	0.0	0.0	2.7	1.2	—
Cash from Operating Activities
Profit Before Tax (per I/S)	143.3	177.4	184.2	200.6	201.8
+ Total Adjustments (incl. Working Capital)	56.9	-80.3	12.4	-66.8	—
Cash from Operations (pre-tax)	200.2	97.1	196.6	133.8	—
+ Income Taxes Paid	47.8	53.9	59.2	68.8	—
Cash from Operating Activities	152.4	43.3	137.4	65.1	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	32.9	131.3	158.5	264.7	—
+ Disp of Fixed Assets	1.7	5.5	0.0	24.2	—
+ Purchase of Investments (Equity / Debt)	0.0	9.0	17.8	0.0	—
+ Sale of Investments (Equity / Debt)	-13.7	0.0	0.0	23.1	—
+ Acq of Subsidiaries / Businesses (net)	98.5	17.7	0.3	0.0	—
+ Dividends Received — Investing	0.2	0.1	0.0	1.2	—
+ Interest Received — Investing	2.1	2.6	0.7	1.5	—
+ Other Inflows / (Outflows) — Investing	-39.7	46.6	-7.8	-4.8	—
Cash from Investing Activities	-180.9	-103.2	-183.7	-219.5	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	4.2	0.0	0.0	0.8	—
+ Proceeds from Other Equity Instruments	0.0	3.8	5.1	0.0	—
+ Proceeds from Borrowings	65.5	43.5	120.7	239.6	—
+ Repayment of Borrowings	0.0	11.6	38.6	19.6	—
+ Payment of Lease Liabilities	0.0	0.8	3.0	6.6	—
+ Interest Paid	6.1	16.0	16.5	25.2	—
+ Dividends Paid	2.8	2.8	2.8	2.8	—
Cash from Financing Activities	60.9	16.2	64.9	186.3	—
Net Changes in Cash (pre-FX)	32.4	-43.8	18.6	31.9	—
+ Effect of FX Rate Changes on Cash	0.0	-0.3	0.4	-0.8	—
Net Changes in Cash	32.4	-44.0	19.0	31.1	—
Closing Cash	69.8	25.2	—	—	—
Reference Items
EBITDA	223.0	249.8	265.1	285.9	313.7
EBITDA Margin %	13.47	13.64	12.74	11.93	11.79
Free Cash Flow (CFO − Capex)	119.5	-88.0	-21.1	-199.6	-199.6
Free Cash Flow to Equity	—	-72.1	44.6	-4.8	—
Free Cash Flow per Basic Share	21.58	-15.89	-3.80	-36.04	-36.04
Cash Flow to Net Income	1.42	0.33	1.01	0.44	—
Cash Paid for Taxes	47.8	53.9	59.2	68.8	—
Cash Paid for Interest	6.1	16.0	16.5	25.2	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.